SYBX
SYNLOGIC, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.96
−3.99%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -11.6%
- EPS
- +38.1%
- Free cash flow
- -19.5%
- Operating cash flow
- -19.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +84.6%
- EBIT
- +90.2%
- Net income
- +95.7%
- EPS
- +95.8%
- Free cash flow
- +86.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026